Justin Zelin
Stock Analyst at BTIG
(1.66)
# 3,360
Out of 5,179 analysts
40
Total ratings
29.27%
Success rate
-9.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $7.38 | +21.95% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $21.46 | +109.69% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $23.49 | +138.40% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $23.04 | +117.01% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $0.99 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.30 | +515.38% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $30.46 | +103.55% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.41 | +1,848.84% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $32.52 | +284.38% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $1.05 | +566.67% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.04 | +296.83% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $38.83 | +8.16% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.72 | +110,550.07% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.44 | +209.10% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $6.47 | +2,372.95% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.60 | +900.00% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $16.80 | +435.71% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $7.74 | +300.52% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $36.04 | -56.99% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $7.38
Upside: +21.95%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $21.46
Upside: +109.69%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $23.49
Upside: +138.40%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $23.04
Upside: +117.01%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.99
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.30
Upside: +515.38%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $30.46
Upside: +103.55%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.41
Upside: +1,848.84%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $32.52
Upside: +284.38%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $1.05
Upside: +566.67%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $5.04
Upside: +296.83%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $38.83
Upside: +8.16%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.72
Upside: +110,550.07%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.44
Upside: +209.10%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $6.47
Upside: +2,372.95%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.60
Upside: +900.00%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $16.80
Upside: +435.71%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $7.74
Upside: +300.52%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $36.04
Upside: -56.99%